Chest
Original Research: AsthmaImprovements in Distal Lung Function Correlate With Asthma Symptoms After Treatment With Oral Montelukast
Section snippets
Subjects
Nineteen subjects 18 to 60 years of age with asthma, as defined by the American Thoracic Society,11 were recruited for the study. Subjects were required to have had a diagnosis of asthma for at least 6 months, to demonstrate an increase in FEV1 or FVC of ≥ 200 mL and 12% after receiving therapy with an inhaled bronchodilator, or to have a provocative concentration of methacholine causing a 20% fall in FEV1 (PC20) of < 8 mg/mL. In addition, they were required to demonstrate a residual volume
Subjects
Nineteen subjects met inclusion criteria, and their baseline characteristics are presented in Table 1. The subjects were considered to have mild asthma when FEV1 was 83% predicted, TLC was 107% predicted, and the geometric mean of the PC20 was 0.79 mg/mL.
Lung Physiology
See Table 2 for a summary of lung function studies prior to each treatment period and the change with montelukast and placebo, respectively. The p values represent a comparison between the change in the variable while the patient was receiving
Discussion
This study demonstrates that therapy with montelukast significantly improves asthma symptoms as well as physiology in both the proximal and distal lung compartments. The improvement in more proximal lung physiology is reflected by improvements in sGaw, while the distal lung compartment improvements are perhaps best reflected by a reduction in RV. The FEV1, a global measure of airway function, reflects the physiology of both the proximal and distal lung compartments, the conditions of which were
Conclusion
In summary, we determined that the systemic delivery of montelukast, at doses used clinically for the treatment of asthma, improved proximal and distal lung function in patients with mild asthma, particularly in those patients with evidence of air trapping, as demonstrated by an increase in RV. These improvements in distal lung function correlated significantly with improvements in asthma symptoms. This finding may explain why, in the face of modest FEV1 improvements with montelukast therapy,
References (30)
- et al.
A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist: Montelukast Asthma Study Group
J Allergy Clin Immunol
(1998) - et al.
Effect of montelukast on exhaled leukotrienes and quality of life in asthmatic patients
Chest
(2005) - et al.
Effect of HFA-flunisolide on peripheral lung inflammation in asthma
J Allergy Clin Immunol
(2003) - et al.
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
J Allergy Clin Immunol
(2001) - et al.
Physiologic correlates of distal lung inflammation in asthma
J Allergy Clin Immunol
(2004) - et al.
Risk factors for near-fatal asthma
Chest
(2004) - et al.
Bronchoscopic evaluation of severe asthma: persistent inflammation associated with high dose glucocorticoids
Am J Respir Crit Care Med
(1997) - et al.
Alveolar tissue inflammation in asthma
Am J Respir Crit Care Med
(1996) - et al.
Lymphocyte and eosinophil influx into alveolar tissue in nocturnal asthma
Am J Respir Crit Care Med
(1999) - et al.
The physiological basis of common pulmonary function tests
Arch Environ Health
(1967)
Abnormal alveolar attachments with decreased elastic fiber content in distal lung in fatal asthma
Am J Respir Crit Care Med
Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction
N Engl J Med
Montelukast added to inhaled beclomethasone in treatment of asthma: Montelukast/Beclomethasone Additivity Group
Am J Respir Crit Care Med
Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Montelukast/Beclomethasone Study Group
Ann Intern Med
American Thoracic Society Board of Directors. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma
Am Rev Respir Dis
Cited by (59)
Small airways in asthma: From inflammation and pathophysiology to treatment response
2024, Respiratory MedicineStatus Asthmaticus Gravidus: Emergency and Critical Care Management of Acute Severe Asthma During Pregnancy
2023, Immunology and Allergy Clinics of North AmericaResidual Volume Responsiveness Testing May Improve the Detection of Reversible Airway Obstruction in Asthma
2022, Journal of Allergy and Clinical Immunology: In PracticeCurrent state and future prospect of the therapeutic strategy targeting cysteinyl leukotriene metabolism in asthma
2019, Respiratory InvestigationCitation Excerpt :These agents also possess anti-inflammatory properties and reduce the number of eosinophils, lymphocytes, and mast cells in sputum and bronchial biopsy tissue [59], while also decreasing the levels of fractional exhaled nitric oxide (FeNO), which is a biomarker that reflects airway eosinophilic inflammation [60,61]. Additionally, LTRAs have the potential benefits of suppressing inflammation in the peripheral airway, which is a difficult location to reach for inhaled drugs [62]. On the basis of these pharmacological effects, the efficacy of LTRAs as a first-line monotherapy has been shown in adult patients with stable mild and moderate persistent asthma [63,64].
Management of Severe Asthma before Referral to the Severe Asthma Specialist
2017, Journal of Allergy and Clinical Immunology: In PracticeCitation Excerpt :For example, in Severe Asthma Research Program, individuals with more severe dysfunction of small airways, measured by reduction in spirometric measurement of FEF25-75, had more frequent asthma symptoms and higher health care utilization, and were characterized by higher FeNO, IgE levels, and bronchial hyperreactivity.99 Small airway dysfunction or air trapping is also positively correlated with increased symptoms,100 exacerbation frequency in both adults and children with exacerbation-prone asthma,101 and with systemic steroid use.12 Notably, drug distribution may contribute to success of topically inhaled medications, particularly in the setting of severe asthma with small airways disease.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).
Drs. Kraft, Irvin, and Wenzel have served as speakers and consultants for Merck, Inc. Dr. Cairns received salary support and has been a speaker for Merck, Inc. Dr. Ellison and Mr. Pak have reported to the ACCP that no significant conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
This research was supported by Merck, Inc.